Trabodenoson: Completed Phase III enrollment

Inotek completed enrollment of about 335 patients in the double-blind, U.S. Phase III MATrX-1 trial comparing topical trabodenoson vs. twice-daily placebo or 0.5% timolol in both eyes for 12 weeks. Pa...